EGFR E746_S752delinsD

CI-VAR-00000836Explore in graph →CIViC 1009 rs121913423

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma5
EGFR E746_S752delinsD	Afatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2571 In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC	civic
EGFR E746_S752delinsD	Afatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2572 A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.